drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
Humanized, afucosylated IgG1 monoclonal antibody (KW-0761) targeting CCR4 that induces ADCC via NK-cell Fcγ receptors, depleting CCR4+ T cells including HTLV-1–infected clones and regulatory T cells, and modulating the CCR4–CCL17/CCL22 axis.
nci_thesaurus_concept_id
C62510
nci_thesaurus_preferred_term
Mogamulizumab
nci_thesaurus_definition
A humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities. Mogamulizumab selectively binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, and chemokine-mediated angiogenesis. In addition, this agent may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against CCR4-positive T cells. CCR4, a G-coupled-protein receptor for C-C chemokines such MIP-1, RANTES, TARC and MCP-1, is expressed on the surfaces of some types of T cells, endothelial cells, and some types of neurons. CCR4, also known as CD194, may be overexpressed on adult T-cell lymphoma (ATL) and peripheral T-cell lymphoma (PTCL) cells.
drug_mesh_term
Mogamulizumab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized, afucosylated IgG1 monoclonal antibody targeting CCR4; blocks CCR4-chemokine signaling and triggers enhanced ADCC via NK-cell Fc-gamma receptors, leading to depletion of CCR4+ T cells (including HTLV-1–infected clones and regulatory T cells) and modulation of the CCL17/CCL22 axis.
drug_name
Mogamulizumab
nct_id_drug_ref
NCT06698003